{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.89","upperLimit":"4.76","value":"1.87"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"96"}],"units":"Participants"}],"description":"Time to Objective Response was defined as the time in months from first dose date to the first date of objective disease response (later confirmed) and time to CCR was defined as the time in months from first dose date to the first date of CCR (later confirmed).","dispersionType":"Full Range","groups":[{"description":"Regimen was 14 mg/m2 IV over a 4-hour period on Days 1, 8, and 15 of a 28-day cycle. The protocol included 6 cycles of treatment; responding patients and patients who achieved at least Stable Disease (SD) had the option of continuing treatment beyond 6 cycles at the discretion of the Investigator and based on local regulations.","id":"OG000","title":"Romidepsin"}],"paramType":"MEDIAN","populationDescription":"Efficacy analysis based on interim analysis of data for as treated population","reportingStatus":"POSTED","timeFrame":"Up to 10 months","title":"Time to Objective Disease Response","type":"SECONDARY","unitOfMeasure":"Months"}